Boule Diagnostics AB divests holdings in associated company

Ernst Westman, CEO Boule Diagnostics AB comments;
“We will continue to grow and take market share on the global market for hematology diagnostics, and that is where we will continue to centre our efforts. The sale of Nordic Biolabs completes the transformation of Boule Diagnostics to an international diagnostics company with focus on human and veterinary hematology diagnostics. It is also our view that this is a suitable time to divest our holdings.”

Nordic Biolabs was formed in 2004 as a merger between Boule Nordic and LabDesign in an effort to create a strong life science distribution business with focus on the Nordic market. Boule’s holdings in Nordic Biolabs will be acquired by the remaining shareholders of Nordic Biolabs; Thomas Busch, Jan Skaring and Claes Hedberg.

For more information, please contact:
Ernst Westman, President CEO Boule Diagnostics AB, telephone +46 708-60 88 63

The information disclosed in this press release is such that Boule Diagnostics AB is required to make this information public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for publication on December 16, 2011 at 08.00 am (CET).

TO THE EDITORS
 
About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics’ share is, since 2011, traded on NASDAQ OMX Nordic. www.boule.se

PDF